Q2 2023 Holdings
Filed 2023-08-14 | 43 holdings | $7.4B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc(APLS) | Common | 03753U106 | $1.0B | 11,111,111 | 13.7% |
| Horizon Therapeutics PLC | Common | G46188101 | $720.0M | 7,000,000 | 9.8% |
| United Therapeutics Corp(UTHR) | Common | 91307C102 | $642.4M | 2,909,999 | 8.7% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $530.0M | 4,627,888 | 7.2% |
| Argenx SE(ARGX) | Sponsored ADR | 04016X101 | $492.4M | 1,263,500 | 6.7% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $350.0M | 1,515,151 | 4.7% |
| Biomarin Pharmaceutical Inc(BMRN) | Common | 09061G101 | $346.7M | 4,000,000 | 4.7% |
| Amicus Therapeutics Inc(FOLD) | Common | 03152W109 | $344.1M | 27,400,000 | 4.7% |
| Seagen Inc(SGENUSD) | Common | 81181C104 | $338.7M | 1,759,606 | 4.6% |
| Ascendis Pharma(ASND) | Sponsored ADR | 04351P101 | $319.6M | 3,580,555 | 4.3% |
| Iveric BIO Inc(OPHTEUR) | Common | 46583P102 | $316.7M | 8,050,000 | 4.3% |
| Krystal Biotech Inc(KRYS) | Common | 501147102 | $300.6M | 2,560,811 | 4.1% |
| Alnylam Pharmaceuticals Inc(ALNY) | Common | 02043Q107 | $209.9M | 1,105,000 | 2.8% |
| Mirati Therapeutics Inc(MRTXEUR) | Common | 60468T105 | $200.7M | 5,555,555 | 2.7% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $188.7M | 4,900,000 | 2.6% |
| Cymabay Therapeutics Inc(CBAYUSD) | Common | 23257D103 | $112.8M | 10,300,000 | 1.5% |
| Dice Therapeutics Inc | Common | 23345J104 | $102.2M | 2,199,342 | 1.4% |
| Kymera Therapeutics Inc(KYMR) | Common | 501575104 | $88.6M | 3,855,000 | 1.2% |
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $88.0M | 1,725,000 | 1.2% |
| Biocryst Pharmaceuticals Inc(BCRX) | Common | 09058V103 | $84.9M | 12,055,000 | 1.2% |
| Nuvalent Inc(NUVL) | Common | 670703107 | $67.5M | 1,600,000 | 0.9% |
| Roivant Sciences LTD(ROIV) | Common | G76279101 | $58.5M | 5,806,162 | 0.8% |
| Syndax Pharmaceuticals Inc(SNDX) | Common | 87164F105 | $55.5M | 2,650,000 | 0.8% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $47.2M | 6,700,000 | 0.6% |
| Mannkind Corp(MNKD) | Common | 56400P706 | $37.0M | 9,100,000 | 0.5% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $34.6M | 750,000 | 0.5% |
| Marinus Pharmaceuticals Inc(MRNS*) | Common | 56854Q200 | $34.2M | 3,150,000 | 0.5% |
| Kura Oncology Inc(KURA) | Common | 50127T109 | $32.9M | 3,105,000 | 0.4% |
| Monte Rosa Therapeutics Inc(GLUE) | Common | 61225M102 | $31.1M | 4,535,000 | 0.4% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $27.8M | 2,510,000 | 0.4% |
| Design Therapeutics Inc(DSGN) | Common | 25056L103 | $22.1M | 3,500,000 | 0.3% |
| Mersana Therapeutics Inc | Common | 59045L106 | $21.0M | 6,375,000 | 0.3% |
| Aadi Biosciences Inc(WHWK) | Common | 00032Q104 | $19.5M | 2,849,402 | 0.3% |
| PMV Pharmaceuticals Inc(PMVP) | Common | 69353Y103 | $19.2M | 3,060,000 | 0.3% |
| Verrica Pharmaceuticals Inc | Common | 92511W108 | $17.0M | 2,954,064 | 0.2% |
| Arrowhead Pharmaceuticals Inc(ARWR) | Common | 04280A100 | $12.7M | 357,403 | 0.2% |
| Seres Therapeutics Inc(MCRB1EUR) | Common | 81750R102 | $12.0M | 2,500,000 | 0.2% |
| Ikena Oncology Inc | Common | 45175G108 | $10.8M | 1,640,000 | 0.1% |
| Fennec Pharmaceuticals Inc(FENC) | Common | 31447P100 | $10.6M | 1,200,000 | 0.1% |
| Tango Therapeutics Inc(TNGX) | Common | 87583X109 | $5.4M | 1,640,000 | 0.1% |
| IO Biotech Inc(IOBT) | Common | 449778109 | $4.0M | 2,055,883 | 0.1% |
| Talaris Therapeutics Inc | Common | 87410C104 | $1.5M | 500,000 | 0.0% |
| Aeglea Biotherapeutics Inc(AGLEUSD) | Common | 00773J103 | $129.1K | 286,459 | 0.0% |